(Adnkronos) - “La malattia psoriasica è una malattia in cui moltissimi domini diversi possono essere coinvolti, dalla cute, alle articolazioni, ai tendini, alle unghie, fino alla colonna. Tutto questo spesso insieme a delle comorbilità. È chiaro che dobbiamo considerare questa malattia come un unicum, come una storia che ogni paziente ha da raccontare e che noi medici dobbiamo assolutamente interpretare nel suo insieme”. Sono le parole di Roberto Caporali, professore di Reumatologia all’università degli studi di Milano e Direttore dipartimento di reumatologia e scienze mediche, ASST Gaetano Pini-CTO, a margine dell’evento con il quale Ucb ha dato l’annuncio del via libera di Aifa all’estensione della rimborsabilità in Italia di bimekizumab per l’artrite psoriasica attiva, dopo quella ottenuta nel marzo 2023 per la psoriasi a placche da moderata a severa.
Category
🗞
NewsTranscript
00:00The psoriasis disease is a disease caused by many different domains that can be involved.
00:11Just think of the cuticle, the joints, the tendons, the nails, the spine.
00:17All this together often has comorbidities, such as cardiovascular disease, for example.
00:23It is clear that we must consider this disease as a unicum, as a story that every patient has to tell
00:30and that we doctors must interpret it as a whole and not look at it through the window of the clinic.
00:37Bhimikizumab is a new biotechnological drug that is added to the numerous drugs that we already have for the treatment of this disease.
00:45The novelty is in the ability of the drug to have a more complete action,
00:52because it is able to inhibit not only a cytokine in its small part, but to inhibit this cytokine in two parts,
01:00therefore two components of the cytokine itself.
01:02So it is certainly an improvement in the ability to endure a fuller response.
01:07What changes?
01:08It changes that we always need new drugs for our patients
01:12because we have patients who do not respond correctly to the drugs we have.
01:16Second, having a drug that is more complete, of course,
01:21improves our ability to induce a complete response in these patients, such as remission.
01:27We have a series of drugs that can be more or less active at the level of the dermatological component,
01:32at the level of the, let's say, articular component or of the spine.
01:37What we are doing now is working closely with rheumatologists and dermatologists
01:42to identify the best time to use the drugs.
01:46Bimikizumab is a drug that works extremely well on the dermatological component,
01:51like all 17 inhibitor interleukins,
01:54but it also works very well on the skeletal component,
01:58inducing an excellent response in terms of remission in patients who have the particularly active articular component.
02:05From a rheumatological point of view, the drug, the most interesting result
02:10is related to the number of patients who achieve a result called MDA,
02:15that is, Minimal Disease Activity.
02:17This MDA, which is a situation very close to complete remission,
02:21is achieved in a very high percentage of patients,
02:24so this gives us great hope in real life
02:27to achieve the same result in the patients we see in the ward.